化疗联合NKG2A抑制剂抗头颈部鳞状细胞癌作用的研究

doi:10.3969/j.issn.1000-8535.2024.08.006

摘要/Abstract

摘要： 目的研究靶向NKG2A抑制剂抗头颈部鳞状细胞癌（HNSCC）的作用。方法应用GEO和TCGA数据库分析NKG2A及其配体HLA-E单细胞表达情况、与患者预后以及免疫微环境的相关性。构建HNSCC皮下抑制瘤模型,流式细胞技术检测化学治疗（化疗）对免疫检测点NKG2A表达的影响。动物实验验证NKG2A抑制剂以及NKG2A抑制剂联合多西他赛化疗的抗肿瘤作用。结果 NKG2A（KLRC1）主要表达在NK细胞,少量表达在T淋巴细胞。HNSCC肿瘤高表达NKG2A/HLA-E（P<0.01）,与患者不良预后密切相关;肿瘤微环境中NKG2A/HLA-E与多个免疫细胞浸润以及免疫检测点表达密切相关（P<0.01）。动物实验显示化疗能上调T、B淋巴细胞表达免疫检查点NKG2A的表达水平（P<0.01）;化疗的基础上联合NKG2A抑制剂能更有效地介导抗肿瘤作用（P=0.013）。结论化疗基础上联合NKG2A抑制剂能更有效地介导抗肿瘤作用,为探索HNSCC临床新策略提供实验和理论基础。

关键词: 头颈部鳞状细胞癌, NKG2A抑制剂, 化疗, 抗肿瘤作用

Abstract: Objective To investigate the anti-tumor effects of NKG2A inhibitor on head and neck squamous cell carcinoma（HNSCC）．Methods The single-cell expression of NKG2A ,its ligand HLA-E and their correlations with patient prognosis and immune microenvironment were analyzed in GEO and TCGA databases．The subcutaneous tumor model of HNSCC was constructed,and the effects of chemotherapy on the expression of NKG2A on T and B lymphocytes were detected by flow cytometry．Animal experiments were used to confirmed the anti-tumor effects of NKG2A inhibitor and NKG2A inhibitors combined with docetaxel．Results NKG2A（KLRC1）was mainly expressed in NK cells,and a small amount was expressed in T lymphocytes．The high expression of NKG2A/HLA-E in HNSCC tumors（P<0.01）were closely related to poor prognosis．NKG2A/HLA-E in tumor microenvironment were closely related to the infiltration of multiple immune cells and the expression of immune checkpoints（P<0.01）．Animal experiments showed that chemotherapy could up-regulate the expression of NKG2A in T and B lymphocytes（P<0.01）．Chemotherapy in combination with NKG2A inhibitor could mediate more effective antitumor effects in HNSCC（P=0.013）．Conclusions Combined with NKG2A inhibitor on the basis of chemotherapy can mediate more effective anti-tumor effects,and this study may provide experimental and theoretical basis for exploring new clinical strategies of HNSCC．

Key words: head and neck squamous cell carcinoma, NKG2A inhibitor, chemotherapy, anti-tumor effect

方喜生, 刘霞, 王秀艳, 彭倩, 吕琳, 刘国龙. 化疗联合NKG2A抑制剂抗头颈部鳞状细胞癌作用的研究[J]. 广州医药, 2024, 55(8): 860-868.

FANG Xisheng, LIU Xia, WANG Xiuyan, PENG Qian, LV Lin, LIU Guolong. Effect of chemotherapy combined with NKG2A inhibitor on head and neck squamous cell carcinoma[J]. Guangzhou Medical Journal, 2024, 55(8): 860-868.

参考文献

[1] SIEGEL REBECCA L,MILLER KIMBERLY D,JEMAL AHMEDIN.Cancer statistics,2018[J].CA:A cancer journal for clinicians,2018,68(1):7-30.
[2] 邬要芬,冯燕英,幸敏清,等.多维化整体护理模式对头颈部恶性肿瘤患者放射性口腔黏膜炎的影响[J].现代医院,2023,23(7):1145-1148.
[3] ARGIRIS A,KARAMOUZIS M V,RABEN D,et al.Head and neck cancer[J].Lancet,2008,371(9625):1695-1709.
[4] BHATIA A,BURTNESS B.Treating head and neck cancer in the age of immunotherapy:A 2023 update[J].Drugs,2023,83(3):217-248.
[5] ANDRÉ P,DENIS C,SOULAS C,et al.Anti-NKG2A mab is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells [J].Cell,2018,175(7):1731-1743.e13.
[6] van MONTFOORT N,BORST L,KORRER M J,et al.NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines[J].Cell,2018,175(7):1744-1755.e15.
[7] ZAGHI E,CALVI M,MARCENARO E,et al.Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy[J].J Leukoc Biol,2019,105(6):1243-1251.
[8] WANG Z,LI B,LI S,et al.Metabolic control of CD47 expression through lat2-mediated amino acid uptake promotes tumor immune evasion[J].Nat commun,2022,13(1):6308.
[9] VINAY D S,RYAN E P,PAWELEC G,et al.Immune evasion in cancer:Mechanistic basis and therapeutic strategies[J].Semin Cancer Biol,2015,35(Suppl):S185-S198.
[10] GOLDMAN M J,CRAFT B,HASTIE M,et al.Visualizing and interpreting cancer genomics data via the Xena platform[J].Nat Biotechnol,2020,38(6):675-678.
[11] LI C,GUAN R,LI W,et al.Single-cell RNA sequencing reveals tumor immune microenvironment in human hypopharygeal squamous cell carcinoma and lymphatic metastasis[J].Front Immunol,2023(14):1168191.
[12] CHANDRASHEKAR D S,KARTHIKEYAN S K,KORLA P K,et al.UALCAN: An update to the integrated cancer data analysis platform[J].Neoplasia,2022(25):18-27.
[13] KANEHISA M,FURUMICHI M,SATO Y,et al.KEGG: Integrating viruses and cellular organisms[J].Nucleic Acids Res,2021,49(D1):D545-D551.
[14] KANEHISA M.Toward understanding the origin and evolution of cellular organisms[J].Protein Sci,2019,28(11):1947-1951.
[15] HÄNZELMANN S,CASTELO R,GUINNEY J.GSVA:Gene set variation analysis for microarray and RNA-seq data[J].BMC Bioinformatics,2013(14):7.
[16] STUART T,BUTLER A,HOFFMAN P,et al.Comprehensive integration of single-cell data[J].Cell,2019,177(7):1888-1902.e21.
[17] CHEN C,HUANG F,LI X,et al.Identification of splicing factors signature predicting prognosis risk and the mechanistic roles of novel oncogenes in HNSCC[J].Biochim Biophys Acta Mol Basis Dis,2024,1870(4):167115.
[18] HUI R,LIU X,FAN Z,et al.The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma[J].J Cancer,2024,15(6):1668-1674.
[19] IKEDA G,MIYAKOSHI J,YAMAMOTO S,et al.Nivolumab in unresectable advanced,recurrent or metastatic esophageal squamous cell carcinoma[J].Future Oncol,2024,20(11):665-677.
[20] WU W J,LIU Q,AN P G,et al.Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma:A real-world retrospective study[J].Front Immunol,2023(14):1282629.
[21] XIE P,YU M,ZHANG B,et al.CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma[J].J Hepatol,2024, 81(1):93-107.
[22] TAO Z Y,WANG L,ZHU W Y,et al.Lingual denervation improves the efficacy of anti-PD-1 immunotherapy in oral squamous cell carcinomas by downregulating TGFβ signaling[J].Cancer Res Commun,2024,4(2):418-430.
[23] MOTZ G T,COUKOS G.Deciphering and reversing tumor immune suppression[J].Immunity,2013,39(1):61-73.
[24] GUBIN M M,ZHANG X,SCHUSTER H,et al.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J].Nature,2014,515(7528):577-581.
[25] ALVAREZ ARIAS D A,KIM H J,ZHOU P,et al.Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity[J].Cancer Immunol Res,2014,2(3):207-216.
[26] 邓修宁. 化疗联合调强放疗治疗老年(≥65岁)局部晚期鼻咽癌的临床疗效[J].广州医药,2023,54(4):40-44.
[27] MERIC-BERNSTAM F,LARKIN J,TABERNERO J,et al.Enhancing anti-tumour efficacy with immunotherapy combinations[J].Lancet,2021,397(10278):1010-1022.
[28] NAJIBI A J,LARKIN K,FENG Z,et al.Chemotherapy dose shapes the expression of immune-interacting markers on cancer cells[J].Cell Mol Bioeng,2022,15(6):535-551.
[29] STINCHCOMBE T E,MIKSAD R A,GOSSAI A,et al.Real-world outcomes for advanced non-small cell lung cancer patients treated with a PD-L1 inhibitor beyond progression[J].Clin Lung Cancer,2020,21(5):389-394.e3.